Safripol a division of KAP Diversified Industrial (Pty) Ltd

Technical Data Sheet

UF 180

Urea Formaldehyde resin

UF 180 is an aqueous Urea Formaldehyde resin typically used as an adhesive in the manufacturing of composite wood products

UF 180 is usually diluted before application to optimize usage.

Acid salts and other hardeners may be added to ensure faster curing.

Typical Applications

- Medium Density Fiberboard
- Chipboard wood products

Appearance:

Translucent to white liquid

PROPERTIES[1]	VALUE	UNIT	TEST METHOD
pH @ 25ºC	7.70 – 8.50	~	EN 1245 E2
Density @ 25ºC	1.280 – 1.295	g/cm^3	EN 542:2003
Brookfield Spindle Viscometer	450 – 700	Centipoise	EN 12092:2001
Viscosity @ 25ºC Ford Cup No. 4	76 – 144	Seconds	ASTM D1200
Solids, 2 h @ 120ºC	64.0 – 66.0	% (m/m)	EN 827:2005
Gel-time @ 96ºC – 98°C	25 – 40	Seconds	EN 9396:2000

[1] Typical values; not to be construed as specification limits.

PACKAGING:	UF 180 is sold in bulk only.
STORAGE & HANDLING:	UF 180 should be stored under cool and dry conditions. Safripol will not replace or re-work resin that has become unusable due to faulty storage or handling. It is the customer's responsibility to ensure that the condition of the resin is monitored at all times. This means measuring and recording the pH, viscosity and temperature of the resin on a daily basis.
SHELF LIFE:	The shelf life is considered to be the time taken for the viscosity to double. The shelf life of UF 180 Urea Formaldehyde resin is dependent on Storage Temperature. Upon ageing, the resin becomes more viscous, and less tolerant of water.
	Storage Conditions / **Shelf Life** 20ºC / 6 weeks 25ºC / 4 weeks 30ºC / 3 weeks 40ºC / 1 week

Safripol a division of KAP Diversified Industrial (Pty) Ltd

Technical Data Sheet

UF 180

Urea Formaldehyde resin

Product Stewardship	At Safripol*, protecting people and the environment will be a part of everything we do and every decision we make. Each employee has a primary responsibility in ensuring that our products and operations meet applicable government standards. Our goal is to eliminate all injuries, prevent adverse environment and health impacts, reduce wastes and emissions and promote resource conservation at every stage of the life cycle of our products. The success of this rests with each and every individual involved with Safripol* products throughout the life cycle.
Customer Notice	Safripol* strongly encourages its customers to review both their manufacturing processes and their applications of Safripol* products from the standpoint of human health and environmental quality to ensure that Safripol* products are not used in ways for which they are not intended or tested. Safripol* personnel are available to answer your questions and to provide reasonable technical support. Safripol* product literature, including safety data sheets, should be consulted prior to use of Safripol* products. Current safety data sheets are available from Safripol*.
Safripol Medical Application Policy	Safripol* will not knowingly sell or sample any product or service ("Product") into any commercial or developmental application that is intended for: a. permanent (Long term) contact with internal body fluids or internal body tissues. Long term is a use which exceeds 72 continuous hours. b. use in cardiac prosthetic devices regardless of the length of time involved; (Cardiac prosthetic devices include, but are not limited to, pacemaker leads and devices, artificial hearts, heart valves, intra-aortic balloons and control systems, and ventricular bypass assisted devices); c. use as a critical component in medical devices that support or sustain human life; or d. use specifically by pregnant women or in applications designed specifically to promote or interfere with human reproduction. Additionally, all Products intended for use in pharmaceutical applications, other than pharmaceutical packaging, must pass the current Pharmaceutical Liability Guidelines. ● New business opportunities require a business assessment prior to sale or sampling of Safripol* products. ● Authorized distributors and resellers will adhere to this medical policy. ● Safripol* does not endorse or claim suitability of their products for specific medical applications. It is the responsibility of the medical device or pharmaceutical manufacturer to determine that the Safripol* product is safe, lawful, and technically suitable for the intended use. SAFRIPOL* MAKES NO WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE SUITABILITY OF ANY SAFRIPOL* PRODUCT FOR USE IN MEDICAL APPLICATIONS.
Disclaimer	The Customer is responsible for determining whether products and the information in this document are appropriate for the Customer's use and for ensuring that the Customer's workplace and disposal/recycling practices of our products and packaging, are in compliance with applicable laws and other governmental enactments. Suitable precautions, as well as the observation of existing laws and regulations regarding formaldehyde emission and waste disposal are the responsibility of the end user. Safripol* assumes no obligation or liability for the information in this document. NO WARRANTIES ARE GIVEN; ALL IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE EXPRESSLY EXCLUDED. NOTICE: If products are described as "experimental" or "developmental": (1) product specifications may not be fully determined; (2) analysis of hazards and caution in handling and use are required; and (3) there is greater potential for Safripol* to change specifications and/or discontinue production.

Additional Information

Contact details

Safripol a division of KAP Diversified Industrial (Pty) Ltd*
P O Box 2000
Piet Retief
2380
South Africa

Website: www.safripol.com

Published:

Piet Retief:
Tel: +27 (0) 17 826 8600

Gauteng:
Tel: +27 (0) 11 575 4549

Email: info@safripol.com

July 2018